+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Graves' Ophthalmopathy Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767365
  • Report
  • April 2019
  • Region: Global
  • 76 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Allergan Plc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Horizon Pharma Plc
  • Ipsen SA
  • Neopharm Ltd
  • MORE
The global clinical trial report- “2019 Graves' Ophthalmopathy Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Graves' Ophthalmopathy. It presents in-depth analysis of Graves' Ophthalmopathy clinical trials across markets and companies. The research work is for providing complete understanding into trends in Graves' Ophthalmopathy.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Graves' Ophthalmopathy clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Graves' Ophthalmopathy

The research work is prepared through extensive and continuous research on Graves' Ophthalmopathy trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Graves' Ophthalmopathy patients are identified
  • The report includes panorama of Graves' Ophthalmopathy clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Graves' Ophthalmopathy clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allergan Plc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Horizon Pharma Plc
  • Ipsen SA
  • Neopharm Ltd
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Graves' Ophthalmopathy Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Graves' Ophthalmopathy Clinical Trials by Region
2.2.2 Average Enrollment of Graves' Ophthalmopathy Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Graves' Ophthalmopathy Treatment, 2019

3. Region wise Graves' Ophthalmopathy Clinical Trials
3.1 Asia Pacific Graves' Ophthalmopathy Clinical Trials by Country
3.2 Europe Graves' Ophthalmopathy Clinical Trials by Country
3.3 North America Graves' Ophthalmopathy Clinical Trials by Country
3.4 Middle East and Africa Graves' Ophthalmopathy Clinical Trials by Country
3.5 South and Central America Graves' Ophthalmopathy Clinical Trials by Country

4. Graves' Ophthalmopathy Clinical Trial Trends
4.1 Start Year wise Graves' Ophthalmopathy Clinical Trials
4.2 Phase wise Graves' Ophthalmopathy Clinical Trials
4.3 Trial Status wise Graves' Ophthalmopathy Clinical Trials
4.4 Trial Type wise Graves' Ophthalmopathy Clinical Trials

5. Graves' Ophthalmopathy Average Enrollment Trends
5.1 Average Enrollment in Graves' Ophthalmopathy Trials by Year
5.2 Average Enrollment in Graves' Ophthalmopathy Trials by Phase
5.3 Average Enrollment in Graves' Ophthalmopathy Trials by Status
5.4 Average Enrollment in Graves' Ophthalmopathy Trials by Type of Trial

6. Companies Participating in Graves' Ophthalmopathy Clinical Trials
6.1 Graves' Ophthalmopathy Trials by Sponsor Type
6.2 Graves' Ophthalmopathy Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Graves' Ophthalmopathy Trials- Phase 1
7.2 Graves' Ophthalmopathy Trials- Phase 2
7.3 Graves' Ophthalmopathy Trials- Phase 3
7.4 Graves' Ophthalmopathy Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Graves' Ophthalmopathy Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Graves' Ophthalmopathy Clinical Trials and Enrolment
Figure 5: Europe - Country wise Graves' Ophthalmopathy Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Graves' Ophthalmopathy Clinical Trials and Enrolment
Figure 7: North America - Country wise Graves' Ophthalmopathy Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Graves' Ophthalmopathy Clinical Trials and Enrolment
Figure 9: Graves' Ophthalmopathy Clinical Trials by Phase
Figure 10: Graves' Ophthalmopathy Clinical Trials by Trial Status
Figure 11: Graves' Ophthalmopathy Clinical Trials by Type
Figure 12: Graves' Ophthalmopathy Clinical Trials by Sponsor Type
Figure 13: Graves' Ophthalmopathy Clinical Trials by Leading Sponsors
Figure 14: Graves' Ophthalmopathy Average Enrollment by Phase
Figure 15: Graves' Ophthalmopathy Average Enrollment by Trial Status
Figure 16: Graves' Ophthalmopathy Average Enrollment by Type
Figure 17: Graves' Ophthalmopathy- Average Enrolment by Type of Sponsors
Figure 18: Graves' Ophthalmopathy- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Graves' Ophthalmopathy Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Graves' Ophthalmopathy Clinical Trials and Enrolment
Table 5: Europe - Country wise Graves' Ophthalmopathy Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Graves' Ophthalmopathy Clinical Trials and Enrolment
Table 7: North America - Country wise Graves' Ophthalmopathy Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Graves' Ophthalmopathy Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Graves' Ophthalmopathy Average Enrollment by Phase
Table 15: Graves' Ophthalmopathy Average Enrollment by Trial Status
Table 16: Graves' Ophthalmopathy Average Enrollment by Type
Table 17: Graves' Ophthalmopathy- Average Enrolment by Type of Sponsors
Table 18: Graves' Ophthalmopathy- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3
  • Allergan Plc
  • Enceladus Pharmaceuticals BV
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Horizon Pharma Plc
  • Ipsen SA
  • Neopharm Ltd
  • Neothetics Inc
  • Neovii Pharmaceuticals AG
  • Novartis AG
Note: Product cover images may vary from those shown
Adroll
adroll